News

If you sized SANA small after the May post, the thesis is tracking; consider letting winners run while watching for pullbacks ...
In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
Eli Lilly (NYSE: LLY) led the way in pharma M&A during June. The US pharma major announced two major deals in the month, both ...
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...
Wall Street Zen downgraded Eli Lilly from a "buy" to a "hold" rating, signaling caution amid a flurry of mixed analyst views. Despite this, Eli Lilly still holds strong support from other firms like ...
Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...
As the weight loss treatment space reaches a new saturation point, Novo Nordisk, Eli Lilly and their closest—but still distant—competitors continue to vie for a greater share of the ever- expanding ...
Kinase Inhibitors in Autoimmune Diseases Market Research 2025-2035, Featuring Pfizer, Eli Lilly and Co, Reistone Biopharma, Incyte, BMS, Galapagos, Aclaris Therapeutics, Kadmon, Sanofi, Ono - ...